（株）陽進堂

Yoshindo, a **biopharmaceutical** company founded in **1962**, is at the forefront of pioneering pharmaceutical research and development. With a slogan of "Pioneering the future of pharmaceuticals through innovative biopharmaceutical ventures and global biosimilar development," the company is actively engaged in groundbreaking initiatives to address the future needs of the pharmaceutical industry. One of Yoshindo's key ventures is in the contract manufacturing of **biopharmaceuticals**, a departure from its traditional focus on generics. This move signifies the company's strategic shift towards innovative solutions in pharmaceuticals. Moreover, Yoshindo, in collaboration with India's Rupin Limited, has established YL Biologics, a joint venture focused on global **biosimilar development** for the treatment of rheumatoid arthritis. Emblem is leading the charge in this endeavor, and YL Biologics manages the manufacturing and sales operations in Japan. Yoshindo operates in the **biotechnology**, **health care**, and **pharmaceutical** industries, positioning itself as a key player in shaping the future of medicine. While specific details about the company's headquarters, last investment, and investors are not available at this time, the company's focus on innovative biopharmaceutical ventures and global biosimilar development demonstrates its commitment to driving advancements in the pharmaceutical sector.